Biotech company Pharming Group has appointed Dr Karl Keegan as chief financial officer (CFO). Keegan will be responsible for all financial and financing activities, corporate communications and investor relations. In addition, he will work together with Dr Sijmen de Vries, chief executive officer (CEO), in furthering the company’s business development activities.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.